Legal, clinical and commercial risk associated with GLP-1 drugs
Legal, clinical and commercial risk associated with GLP-1 drugs
Podcast
Legal, clinical and commercial risk associated with GLP-1 drugs
Podcast
Charles explained that compounded GLP-1s have seen a significant rise in popularity worldwide, resulting in supply and demand challenges. He noted that one of the primary concerns with compounded GLP-1s is that they are not assessed or tested by the relevant regulators, such as the FDA in the United States or SAHPRA in South Africa.
Charles also highlighted concerns about the emergence of unregulated compounded drugs in the market, particularly products containing active pharmaceutical ingredients that are not registered with SAHPRA. He noted that this raises serious safety concerns, as regulators are unable to verify the quality, safety, or potential effects of these products on patients.
In addition, Charles referred to recent communications issued by SAHPRA indicating that compounded GLP-1 medicines may soon be considered undesirable due to safety concerns, meaning they can no longer be sold in South Africa.
Click here to listen.
The information and material published on this website is provided for general purposes only and does not constitute legal advice. We make every effort to ensure that the content is updated regularly and to offer the most current and accurate information. Please consult one of our lawyers on any specific legal problem or matter. We accept no responsibility for any loss or damage, whether direct or consequential, which may arise from reliance on the information contained in these pages. Please refer to our full terms and conditions. Copyright © 2026 Cliffe Dekker Hofmeyr. All rights reserved. For permission to reproduce an article or publication, please contact us cliffedekkerhofmeyr@cdhlegal.com.
Subscribe
We support our clients’ strategic and operational needs by offering innovative, integrated and high quality thought leadership. To stay up to date on the latest legal developments that may potentially impact your business, subscribe to our alerts, seminar and webinar invitations.
Subscribe
